Faculty Publications

Publications for Matthew K. Robinson (2004 - 2009)

View Interaction Graph

The following publications are sorted by year and first author. Click on the investigator listed to the right of the citation to find all citations attributed to that investigator. Click on the citation title to see the abstract.

Found 21 publications.


Printer Print View
Publication Investigator(s)
Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA, Marks JD, Waldmann TA, Brechbiel MW, Adams GP. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin Cancer Res. 2008 Feb;14(3):875-82.
Adams
Robinson
Yuan QA, Robinson MK, Simmons HH, Russeva M, Adams GP. Isolation of anti-MISIIR scFv molecules from a phage display library by cell sorter biopanning. Cancer Immunology Immunotherapy. 2008 Mar;57(3):367-78.
Adams
Robinson
Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, Adams GP. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer. 2008 Nov 4;99(9):1415-25.
Adams
von Mehren
Robinson
Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA, Marks JD, Waldmann TA, Brechbiel MW, Adams GP. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin Cancer Res. 2008 Feb 1;14(3):875-82.
Adams
Robinson
Yuan QA, Robinson MK, Simmons HH, Russeva M, Adams GP. Isolation of anti-MISIIR scFv molecules from a phage display library by cell sorter biopanning. Cancer Immunol Immunother. 2008 Mar;57(3):367-78.
Adams
Robinson
Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, Adams GP. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer. 2008 Oct;99(9):1415-25.
Adams
von Mehren
Robinson
Loo L, Robinson MK, Adams GP. Antibody engineering principles and applications. Cancer J. 2008 May-Jun;14(3):149-53.
Adams
Robinson
Yuan QA, Robinson MK, Simmons HH, Russeva M, Adams GP. Isolation of anti-MISIIR scFv molecules from a phage display library by cell sorter biopanning. Cancer Immunol Immunother. 2007;.
Adams
Robinson
Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol. 2007 Sep 1;179(5):2815-23.
Weiner
Robinson
Borghaei H, Robinson MK, Weiner LM. Monoclonal antibody therapy of cancer. Immunotherapy of Cancer. 2006;:487-502.
Weiner
Borghaei
Robinson
Yuan Q, Simmons HH, Robinson MK, Russeva M, Marasco WA, Adams GP. Development of engineered antibodies specific for the Muellerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer. Molecular Cancer Therapeutics. 2006;5(8):2096-105.
Adams
Robinson
Adams GP, Robinson MK, Liu JL, Shaller C, Tang Y, Marks JD, Weiner LM. Examining the roles of affinity and avidity in the tumor targeting properties of anti-HER2 monoclonal antibodies and single-chain Fv molecules. Tumor Biology. 2006;27:1.
Adams
Weiner
Robinson
Borghaei H, Robinson MK, Weiner LM. Monoclonal antibody therapy of cancer. In: Disis ML, editor. Immunotherapy of cancer. Totowa, N.J.: Humana Press; 2006. p. 487-502.
Weiner
Borghaei
Robinson
Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, Trotter DE, Adams GP. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res. 2005;65(4):1471-8.
Adams
Robinson
Robinson MK, Russeva M, Horak EM, Heitner T, Simmons HH, Shaller CC, Reid M, Hodge K, Garrison J, Tesfaye A, Marks JD, Weiner LM, Adams GP. A bispecific single-chain Fv molecule targeting HER2 and HER3 exhibits tumor-targeting specificity in vivo and a therapeutic effect in vitro. Clin Cancer Res. 2005 Part;11(24):8983S-8983S.
Adams
Weiner
Robinson
Horak E, Heitner T, Robinson MK, Simmons HH, Garrison J, Russeva M, Furmanova P, Lou J, Zhou Y, Yuan Q, Weiner LM, Adams GP, Marks JD. Isolation of scFvs to In Vitro Produced Extracellular Domains of EGFR Family Members. Cancer Biotherapy & Radiopharmaceuticals. 2005;20(6):603-13.
Adams
Weiner
Robinson
Robinson M, Shaller C, Doss M, Narayanan D, Marks J, Adler L, Trotter DG, Adams G. Anti-HER2 immunopet for the detection of cancer. Cancer Biotherapy and Radiopharmaceuticals. 2004 12 Aug;19(4):517.
Adams
Robinson
Robinson MK, Shaller C, Doss M, Narayanan D, Adler LP, Gonzalez Trotter DE, Adams GP. Pre-clinical development of antibody-based radiotracers for the detection of cancer via positron emission tomography. Abstracts of Papers, 228th ACS National Meeting, Philadelphia, PA, United States, August 22-26, 2004. 2004;:NUCL-011.
Adams
Robinson
Robinson MK, Shaller C, Doss M, Narayanan D, Adler LP, Trotter DE, Adams GP. Pre-clinical development of antibody-based radiotracers for the detection of cancer via positron emission tomography. Abstracts of Papers of the American Chemical Society. 2004 11-NUCL Part 2 AUG 22;228:U5-U6.
Adams
Robinson
Robinson MK, Weiner LM, Adams GP. Improving monoclonal antibodies for cancer therapy. Drug Development Research. 2004 Mar;61(3):172-87.
Adams
Weiner
Robinson
Trotter DE, Manjeshwar RM, Doss M, Shaller C, Robinson MK, Tandon R, Adams GP, Adler LP. Quantitation of small-animal I-124 activity distributions using a clinical PET/CT scanner. J Nucl Med. 2004 Jul;45(7):1237-44.
Adams
Robinson
Last updated on Saturday, November 21, 2009